Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial

Kong, Qing; Cao, Yuxue; Gao, Zhen; Sun, Jing; Zhang, Hongying; Du, Yanqiu; Lv, Yubao; Zhou, Sihan; Tang, Zihui; Liu, Baojun; Dong, Jingcheng

doi:10.1186/s13063-022-06057-7

Cited by 5 publications

(6 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rat dose of 12.5 g/kg was calculated as 9.1× human dose. The human dose of 125 g/70 kg is referenced to the clinical dose from our two clinical trials (14,19). Five herbal formulas were dissolved in ultrapure water every three days and stored at 4°C.…”

Section: Mbyf Preparationmentioning

confidence: 99%

“…Our randomized controlled trials (RCTs) found MBYF-related herbs could bene t patients with COPD and asthma, including reducing pulmonary function decline, decreasing the level of in ammatory cytokines in serum, and improving life quality (12,13). Two RCTs (Trial registration ID: ChiCTR1900026124, ChiCTR1900021907), are carried out to assess the safety and e cacy of MBYF on patients with COPD and asthma (14). As detailed in our previous report (14)(15)(16), MBYF contains ve herbs: Huang Qi, Yin Yang Huo, Di Huang, Huang Qin, and Chi Shao.…”

Section: Introductionmentioning

confidence: 99%

“…Two RCTs (Trial registration ID: ChiCTR1900026124, ChiCTR1900021907), are carried out to assess the safety and e cacy of MBYF on patients with COPD and asthma (14). As detailed in our previous report (14)(15)(16), MBYF contains ve herbs: Huang Qi, Yin Yang Huo, Di Huang, Huang Qin, and Chi Shao. Furthermore, possible mechanisms of MBYF and its active ingredients in treating asthma have been revealed in mice models of asthma (15,16).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Modified Bushen Yiqi formula attenuates neutrophils recruitment to the lung in rats model of COPD via inhibiting the CXCL1/CXCL5/CXCL8-CXCR2 axis and its downstream STAT and SRC signaling pathways

Kong

Wang

Zhong

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Modified Bushen Yiqi formula (MBYF) demonstrates a therapeutic effect on patients with chronic obstructive pulmonary disease (COPD), however, its mechanism against COPD remains unclear. This study aims to explore the therapeutic effect and mechanisms of MBYF in a rat model of COPD.Methods: The therapeutic effect of MBYF(12.5 g/kg or 25 g/kg) on six-month cigarette smoke (CS)-induced COPD rats model was evaluated through pulmonary function test, inflammatory cell count in bronchoalveolar lavage fluid (BALF), and inflammatory cytokines in serum and BALF. The therapeutic mechanism was revealed by the RNA-sequencing using lung tissue in CS and CS+MBYF group and confirmed via immunohistochemistry, enzyme-linked immunosorbent assay, and Western blot. Results: MBYF remarkably improved the pulmonary function in the rat model of COPD, ameliorated inflammatory cell accumulation in the lung, and reduced the level of inflammatory cytokines in pulmonary and systemic. Mechanistically, MBYF suppressed the chemotactic migration of neutrophils into the lung by down-regulating CXC motif chemokine ligands (CXCL)1/CXCL5/CXCL8-CXC chemokine motif receptor (CXCR)2 axis. Moreover, MBYF inhibited the activation of STAT1, STAT3, and SRC, which are the downstream signaling pathways of the chemokine-chemokines receptor.Conclusion: MBYF attenuated neutrophils recruitment to the lung in the rats model of COPD via inhibiting the CXCL1/CXCL5/CXCL8-CXCR2 axis and its downstream STAT and SRC signaling pathways. Our results support further investigation of MBYF as a promising therapy in the management of COPD.

show abstract

Section: Mbyf Preparationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Modified Bushen Yiqi formula attenuates neutrophils recruitment to the lung in rats model of COPD via inhibiting the CXCL1/CXCL5/CXCL8-CXCR2 axis and its downstream STAT and SRC signaling pathways

Kong

Wang

Zhong

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…It adds Scutellariae radix (Huangqin) and Paeoniae radix rubra (Chishao) to Bushen Yiqi formula (BSYQF), combined with Astragali radix (Huangqi), R. rehmanniae (Dihuang) and Epimedii folium (Yinyanghuo). 14 Chinese medicine has definite pharmacological properties, such as anti-inflammatory, spasmolysis, hemostasis, and phlegm effects. Chinese herbal medicine use is often combined with the patient's excess or deficiency, thus becoming the complex organic that is often used to treat chronic diseases.…”

Section: Introductionmentioning

confidence: 99%

“…Modified Bushen Yiqi formula (MBYF) comprises five Chinese herbal medicines. It adds Scutellariae radix (Huangqin) and Paeoniae radix rubra (Chishao) to Bushen Yiqi formula (BSYQF), combined with Astragali radix (Huangqi), R. rehmanniae (Dihuang) and Epimedii folium (Yinyanghuo) 14 . Chinese medicine has definite pharmacological properties, such as anti‐inflammatory, spasmolysis, hemostasis, and phlegm effects.…”

Section: Introductionmentioning

confidence: 99%

Network pharmacology prediction and molecular docking analysis reveal the mechanism of modified Bushen Yiqi formulas on chronic obstructive pulmonary disease

Choi,

Wu,

et al. 2023

The Journal of Gene Medicine

View full text Add to dashboard Cite

BackgroundThe present study aimed to explore the mechanism of the modified Bushen Yiqi formula (MBYF) in the treatment of chronic obstructive pulmonary disease (COPD) based on network pharmacology and molecular docking.MethodsFirst, the active ingredients and corresponding targets in MBYF were mined through the Traditional Chinese Medicine Systems Pharmacology database. Subsequently, Online Mendelian Inheritance in Man, DrugBank, and GeneCard were used to screen COPD‐related targets. Cytoscape was used to construct a network of candidate components of MBYF in COPD treatment. The overlapping targets of COPD and MBYF were used to treat COPD, and then CytoHubba and CytoNAC plug‐ins in Cytoscape were used for topology analysis to build the core network. In addition, core targets were used for Gene Ontology analysis and enrichment analysis of the Kyoto Encyclopedia of Genes and Genomes. Finally, AutoDock Vina software was used to conduct a molecular docking study on the core active ingredients and core targets to verify the above network pharmacological analysis.ResultsSeventy‐nine active components of MBYF were screened and 261 corresponding targets were found. At the same time, 1307 related targets corresponding to COPD were screened and 111 overlapping targets were matched. By bioinformatics analysis, 10 core targets were identified, and subsequently, enrichment analysis revealed 385 BP, two CC, eight MF and 78 related signaling pathways. The binding of the core active components in MBYF to the core target was further verified by molecular docking, and all showed good binding.ConclusionsThe active components of MBYF, such as quercetin, kaempferol, luteolin, and baicalein, may be the material basis for the treatment of chronic obstructive pulmonary disease. They affect the expression of inflammatory cells and inflammatory factors, protein phosphorylation, and smooth muscle hyperplasia through tumor necrosis factor, interleukin‐17, mitogen‐activated protein kinase, nuclear factor‐kappa B and other signaling pathways.

show abstract

Icariin attenuates asthmatic airway inflammation via modulating alveolar macrophage activation based on network pharmacology and in vivo experiments

Zhu,

Wang,

et al. 2024

The Journal of Gene Medicine

View full text Add to dashboard Cite

BackgroundIcariin (ICA) inhibits inflammatory response in various diseases, but the mechanism underlying ICA treating airway inflammation in asthma needs further understood. We aimed to predict and validate the potential targets of ICA against asthma‐associated airway inflammation using network pharmacology and experiments.MethodsThe ovalbumin‐induced asthma‐associated airway inflammation mice model was established. The effects of ICA were evaluated by behavioral, airway hyperresponsiveness, lung pathological changes, inflammatory cell and cytokines counts. Next, the corresponding targets of ICA were mined via the SEA, CTD, HERB, PharmMapper, Symmap database and the literature. Pubmed‐Gene and GeneCards databases were used to screen asthma and airway inflammation‐related targets. The overlapping targets were used to build an interaction network, analyze gene ontology and enrich pathways. Subsequently, flow cytometry, quantitative real‐time PCR and western blotting were employed for validation.ResultsICA alleviated the airway inflammation of asthma; 402 targets of ICA, 5136 targets of asthma and 4531 targets of airway inflammation were screened; 216 overlapping targets were matched and predicted ICA possesses the potential to modulate asthmatic airway inflammation by macrophage activation/polarization. Additionally, ICA decreased M1 but elevated M2. Potential targets that were disrupted by asthma inflammation were restored by ICA treatment.ConclusionsICA alleviates airway inflammation in asthma by inhibiting the M1 polarization of alveolar macrophages, which is related to metabolic reprogramming. Jun, Jak2, Syk, Tnf, Aldh2, Aldh9a1, Nos1, Nos2 and Nos3 represent potential targets of therapeutic intervention. The present study enhances understanding of the anti‐airway inflammation effects of ICA, especially in asthma.

show abstract

Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial

Cited by 5 publications

References 58 publications

Modified Bushen Yiqi formula attenuates neutrophils recruitment to the lung in rats model of COPD via inhibiting the CXCL1/CXCL5/CXCL8-CXCR2 axis and its downstream STAT and SRC signaling pathways

Modified Bushen Yiqi formula attenuates neutrophils recruitment to the lung in rats model of COPD via inhibiting the CXCL1/CXCL5/CXCL8-CXCR2 axis and its downstream STAT and SRC signaling pathways

Network pharmacology prediction and molecular docking analysis reveal the mechanism of modified Bushen Yiqi formulas on chronic obstructive pulmonary disease

Icariin attenuates asthmatic airway inflammation via modulating alveolar macrophage activation based on network pharmacology and in vivo experiments

Contact Info

Product

Resources

About